Pfizer Inc (PFE)

A CDR lets you bypass any U.S. estate probate tax issues. He owned Pfizer during Covid. Shares have slid since then, below its 200-day moving average. Could be some value at 12x forward PE, but won't touch it.

A very contrarian pick. Why now? Company's pivoting from Covid to cancer. Unfortunately, cancer is a huge market with 1 in 3 being diagnosed. Very strong lineup of potential new blockbuster drugs, management confidence is high on them. Market underappreciates it. Estimated to grow earnings 14%. Trades at 10x, with nice yield of 5.96%.

Near the bottom, won't go much lower. Not if it will work, but when. You get a nice dividend. Tomorrow's winner.

Starting to look at it. Just made an acquisition. Growth rates starting to accelerate.

Currently - stock is at a low price which presents a good buying opportunity. Excellent R&D department. Lots of products coming to the market. Dividend is able to help returns too. Obesity drugs also adding to bottom line (trendy product). 

Hurting. He considers it in a downtrend, lower highs and lower lows, until proven otherwise. Proof that it's over is you start to see consolidation, little zig-zags on the chart. Could start soon, but hasn't yet.

Great company, Covid saviour. Ran up on that, now falling off. Back to more normalized levels. Not his first choice. He owns MRK.

Would recommend buying even with share price weakness. Does not believe market is pricing fairly. Dividend is safe. 

He was looking at it the other day. Trading where it was 30 years ago, despite a slew of acquisitions allowing it to tread water. Big dividend. Bought back shares. Pharma industry in general has been tough for 30 years. FDA has been tougher. Drugs coming out are more narrow-niche. Drug prices are under pressure globally. 

They're having a hangover, post-Covid, after selling vaccines, but those sales have plunged. But at $50 billion in sales, PFE remains a global pharma leader. Pays a 6% dividend. Shares are close to bottoming. Trades at only 12x PE vs. peers like Eli Lily at 70-80x.

Pharma companies today are divided into the haves and have-nots. Eli Lilly and Vertex are in the 'haves' group. He owns Eli Lilly which could be the biggest of the Pharmas. Also Vertex looks good and has a new Cystic Fibrosis drug. Pfizer has little growth and the stock is under pressure. It pays a high dividend but offers no real dividend growth, He prefers lower paying dividend companies with significant dividend growth ahead rather than companies that pay high dividends now. With this theme in mind The ETF, RDVY, holds companies with the ability to grow dividends. His view is that it is a reflating world and that rates could go up more in the next cycle.

Does not own shares. Recent share price erosion a good place to buy. Post Covid-19 demand has fallen, which has reduced revenues. Patent expiration also a major concern. Very old company, but would wait before buying. 

Bought it last year for the 5.9% yield, but with Covid over (and vaccine sales gone), they have nothing. Shares have fallen in the past year. There was disappointment last year, but their obesity pill trial disappointed. Shares are washed out here. There are no expectations, though their drug pipeline is okay.

Not convinced it's based. Pretty good dividend yield of 5.9% is one redeeming quality, appears fairly safe. Underperforming. May have over-invested in Covid-related ideas. Still great brand long term. Stay away for now.

Covid-19 vaccine business fading, but business strong. Valuation coming back down to reasonable levels. Dividend yield ~6%. Expecting further growth with excellent R&D investment. 

Down 43% in 2023 and one of the S&P's dogs, falling sharply after Covid. Pfizer keeps facing patent cliffs for its drugs and hitting profit shortfalls. A comeback is possible, but election years made drugmakers targets. Pays a 5.6% dividend and their Seagen deal which could add an excellent cancer franchise.